HK1258415A1 - 作為致癌基因 erg 的抑制劑的偶氮苯酚 - Google Patents
作為致癌基因 erg 的抑制劑的偶氮苯酚Info
- Publication number
- HK1258415A1 HK1258415A1 HK19100848.3A HK19100848A HK1258415A1 HK 1258415 A1 HK1258415 A1 HK 1258415A1 HK 19100848 A HK19100848 A HK 19100848A HK 1258415 A1 HK1258415 A1 HK 1258415A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- azophenols
- oncogene inhibitors
- erg
- erg oncogene
- inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C245/00—Compounds containing chains of at least two nitrogen atoms with at least one nitrogen-to-nitrogen multiple bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C245/00—Compounds containing chains of at least two nitrogen atoms with at least one nitrogen-to-nitrogen multiple bond
- C07C245/02—Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C245/00—Compounds containing chains of at least two nitrogen atoms with at least one nitrogen-to-nitrogen multiple bond
- C07C245/02—Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides
- C07C245/04—Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides with nitrogen atoms of azo groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/50—Nitrogen atoms bound to hetero atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562216839P | 2015-09-10 | 2015-09-10 | |
PCT/US2016/051098 WO2017044844A1 (en) | 2015-09-10 | 2016-09-09 | Azophenols as erg oncogene inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1258415A1 true HK1258415A1 (zh) | 2019-11-08 |
Family
ID=58240304
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK19100848.3A HK1258415A1 (zh) | 2015-09-10 | 2019-01-17 | 作為致癌基因 erg 的抑制劑的偶氮苯酚 |
Country Status (7)
Country | Link |
---|---|
US (3) | US10238639B2 (zh) |
EP (1) | EP3347001B1 (zh) |
JP (1) | JP6865174B2 (zh) |
AU (1) | AU2016319111B2 (zh) |
CA (1) | CA2981188C (zh) |
HK (1) | HK1258415A1 (zh) |
WO (1) | WO2017044844A1 (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2981188C (en) | 2015-09-10 | 2024-05-28 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Azophenols as erg oncogene inhibitors |
US20230382862A1 (en) * | 2020-06-19 | 2023-11-30 | Sanjay Malhotra | Erg oncogene inhibitors |
CN113616645A (zh) * | 2021-08-27 | 2021-11-09 | 深圳先进技术研究院 | 一种噻唑基重氮萘酚类化合物在制备治疗恶性脑胶质瘤药物中的应用 |
EP4440594A2 (en) * | 2021-11-29 | 2024-10-09 | Dana-Farber Cancer Institute, Inc. | Methods and compositions to modulate riok2 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0738075B2 (ja) | 1986-12-23 | 1995-04-26 | 住友化学工業株式会社 | 新規なフオトレジスト組成物 |
WO1998029257A1 (fr) | 1996-12-27 | 1998-07-09 | Tdk Corporation | Support d'enregistrement optique |
US8143232B2 (en) * | 2009-03-03 | 2012-03-27 | The Regents Of The University Of Michigan | Gene fusion targeted therapy |
CA2925922C (en) * | 2013-09-30 | 2023-03-21 | Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center | Inhibition of thymine dna glycosylase in the treatment of cancer |
CA2981188C (en) | 2015-09-10 | 2024-05-28 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Azophenols as erg oncogene inhibitors |
-
2016
- 2016-09-09 CA CA2981188A patent/CA2981188C/en active Active
- 2016-09-09 WO PCT/US2016/051098 patent/WO2017044844A1/en active Application Filing
- 2016-09-09 JP JP2017550884A patent/JP6865174B2/ja active Active
- 2016-09-09 AU AU2016319111A patent/AU2016319111B2/en active Active
- 2016-09-09 US US15/561,626 patent/US10238639B2/en active Active
- 2016-09-09 EP EP16845184.7A patent/EP3347001B1/en active Active
-
2019
- 2019-01-17 HK HK19100848.3A patent/HK1258415A1/zh unknown
- 2019-02-15 US US16/277,410 patent/US20190336485A1/en not_active Abandoned
-
2021
- 2021-01-26 US US17/158,930 patent/US11648239B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CA2981188C (en) | 2024-05-28 |
JP2018526320A (ja) | 2018-09-13 |
WO2017044844A1 (en) | 2017-03-16 |
US20180169074A1 (en) | 2018-06-21 |
EP3347001A4 (en) | 2019-05-08 |
AU2016319111B2 (en) | 2021-05-06 |
US11648239B2 (en) | 2023-05-16 |
CA2981188A1 (en) | 2017-03-16 |
US20190336485A1 (en) | 2019-11-07 |
US10238639B2 (en) | 2019-03-26 |
EP3347001A1 (en) | 2018-07-18 |
US20210299106A1 (en) | 2021-09-30 |
EP3347001B1 (en) | 2023-07-26 |
AU2016319111A1 (en) | 2017-10-19 |
JP6865174B2 (ja) | 2021-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL287113A (en) | smyd inhibitors | |
HUS2400003I1 (hu) | Kináz inhibitorként alkalmas vegyületek | |
HRP20181899T1 (hr) | Biaril inhibitori kinaze | |
IL254187A0 (en) | beta-tgf inhibitors | |
IL246785A0 (en) | Benzimidazole-2-amines as midh1 inhibitors | |
IL251932B (en) | Benzylpropargyl ether as nitrification inhibitors | |
HK1226398A1 (zh) | 作為midh1抑制劑的苯並咪唑-2-胺 | |
IL248895A0 (en) | Phosphatidylinositol 3-kinase inhibitors | |
GB201403536D0 (en) | Inhibitor compounds | |
GB201513481D0 (en) | Inhibitor compounds | |
IL265139B (en) | Dopamine-b-hydroxylase inhibitors | |
GB201505658D0 (en) | Inhibitor compounds | |
GB201501004D0 (en) | Inhibitors | |
HK1258415A1 (zh) | 作為致癌基因 erg 的抑制劑的偶氮苯酚 | |
GB201612860D0 (en) | Inhibitors | |
HK1251572A1 (zh) | 作為ddr1抑制劑的三氮雜-螺癸酮類化合物 | |
GB201520949D0 (en) | Inhibitors | |
GB201401005D0 (en) | Inhibitor | |
PT3322724T (pt) | Inibidores da il-26 | |
GB201519381D0 (en) | Kinase inhibitors | |
GB201519382D0 (en) | Kinase inhibitors | |
GB201522453D0 (en) | Inhibitor compounds | |
GB201522245D0 (en) | Compounds useful as kinase inhibitors | |
GB201500644D0 (en) | Inhibitor compounds | |
GB201418154D0 (en) | Inhibitors |